and the prognosis remains poor due to drug resistance and the lack of reliable biomarkers. Typical symptoms appear in the early stages, resulting in delayed treatment and poor diagnosis. 4, 12 Therefore, it is important to screen novel and available therapies for gastrointestinal tract cancers.
Presently, immunotherapy has emerged as a promising strategy to treat various types of cancers. PD-1/PD-L1 is a potential biomarker for predicting the survival rate of cancer. The clinical efficacy of PD-1/PD-L1 inhibition has been researched in various malignancies, such as bladder cancer, 13 non-small cell lung cancer (NSCLC) 14 and melanoma. 15 PD-1/PD-L1 inhibitors have been approved for the treatment of more than nine forms of cancer to date. 16 In this review, we summarize PD-1/PD-L1-targeted immunotherapy and its relevant signalling pathway, which may results in a breakthrough for the treatment of gastrointestinal tract cancers, including gastric cancer, CRC, liver cancer and other gastrointestinal tract-related cancers.
| PD -1 AND ITS LI G ANDS
PD-1 protein, a 50-55 kDa type 1 transmembrane glycoprotein, 17 is encoded by the programmed cell death 1 (PCD1) gene, which is a member of the B7 immunoglobulin superfamily 18, 19 
| FUN C TI ON S OF PD -1/PD -L1 AND PD -1/PD -L1 S I G NALLING PATHWAYS IN C AN CER
PD-1 expression may be a novel indicator of T cell immune function. 20 The roles of PD-1 dendritic cells (DCs) in immune regulation have been widely proven. [21] [22] [23] PD-1 was found to be expressed in activated DCs and plays roles in suppressing the production of inflammatory cytokines. 21 Researchers discovered that peptide-pulsed PD-1 knockout (KO) DCs induced high antigen-specific IFN-ɤ production and proliferation of CD4 and CD8 T cells in vivo. 21 Compared with wild-type DCs, PD-1-deficient DCs activated CD8+ T cells to secrete IL-2 and IFNγ and suppressed tumour growth in a mouse model of hepatocellular carcinoma (HCC). 24 Moreover, PD-1 and TIM-3-mediated pathways have significant effects in regulating CD8+ T cell function and maintaining normal pregnancy. 25, 26 Scientists also demonstrated that coexpression of PD-1 and Tim-3 on CD8+ T cells was associated with increased antiatherogenic cytokine production as well as decreased proatherogenic cytokine production in atherosclerosis patients. 27 In addition, Nishimura et al found that PD-1 −/− mice with a C57BL/6 background showed spontaneous development of lupus-like syndromes, including glomerulonephritis and destructive arthritis, 28, 29 which suggested that PD-1 is closely associated with the prevention or development of autoimmune disease. Furthermore, many studies have reported that PD-1 polymorphisms may contribute to the treatment of autoimmune disease. As reported in a previous study, the T allele of the PD-1 rs2227982 polymorphism and the C allele of the PD-L1 rs822336 polymorphism were more frequent in the ankylosing spondylitis patient group than in the control group in a Chinese population, 30 and the frequency of the CT haplotype (PD-1.5 C/T and PD-1.9 T/C) was higher in a Korean ankylosing spondylitis patient group 31 than in the control group, which indicated that PD-1/PD-L1 polymorphisms play a major role in the disease susceptibility of ankylosing spondylitis.
The PD-L/PD1 interaction acts as an immune checkpoint to maintain self-tolerance. 32, 33 As reported in a previous study, the PD-1/PD-L1 interaction can modulate natural killer T cell function to inhibit hepatitis B virus replication. 34 PD-1 in T cells combined with its ligand PD-L1 in tumour cells attenuates antitumour T cell responses and allows tumours to escape these responses 35, 36 ( Figure 1 ). Emerging evidence has shown that inhibition of PD-1/ PD-L1 is related to various malignancies, such as melanoma, 37, 38 NSCLC 37 and renal cell carcinoma. 39 In summary, these findings pro- 
| PD -1/PD -L1 WITH G A S TROINTE S TINAL TR AC T C AN CER S
Gastrointestinal tract cancers are the most common malignancies that threaten global health. CRC, with an estimated 1.4 million cases and 693 900 deaths, is the third most commonly diagnosed cancer in males and the second most commonly diagnosed cancer in females worldwide. 7 Rates of gastric cancer, with an estimated 951 600 new cases and 723 100 deaths, are generally higher in men than in women and vary widely across countries, and the incidence rates are the highest in eastern Asia. 7 Liver cancer is the second leading cause of cancer death in developing countries and in men; this disease is much more common in men than in women
worldwide. An estimated 782,500 new liver cancer cases and 745,500 deaths occurred worldwide according to Global Cancer Statistics (2012). 7 Approximately 70% to 90% of primary liver cancers worldwide are HCC. 42 There were an estimated 455,800 new oesophageal cancer cases and 400,200 deaths in 2012 worldwide. The highest oesophageal cancer incidence rates are found in eastern Asia and in eastern and southern Africa, and the lowest rates are found in western Africa. Oesophageal cancer is usually more common in men than in women. New pancreatic cancer cases occur less frequently than CRC, gastric cancer, liver cancer or oesophageal cancer cases, while the number of deaths caused by this disease is greater than that caused by oesophageal cancer in women worldwide.
Incidence rates and mortality rates of gastrointestinal tract cancers vary in countries and are related to gender. Multiple factors, including environmental factors, intragastric synthesis of carcinogens, genetic factors, infectious agents and pathological changes, are generally recognized as causes of gastrointestinal tract cancers. [8] [9] [10] Gastrointestinal tract cancer screening, reduced prevalence of risk factors, and/or improved treatments would help decrease cancer mortality. Currently, increasing reports have indicated that PD-1/ PD-L1 is associated with gastrointestinal tract cancers. PD-1/PD-L1 has been proven to be an immune regulator and target gene in gastrointestinal tract cancers.
| IN G A S TRI C C AN CER
Studies have indicated that lymphocyte-activation gene 3 (LAG-3)
and PD-1 on CD4+ and CD8+ T cells tended to be upregulated in gastric cancer (GC) patients after gastric cancer surgery. 43 Additional studies revealed that PD-1/PD-L1 mRNA levels, which are positively correlated with one another, were upregulated in GC tissues of patients infected with Helicobacter pylori (Hp) and Epstein-Barr virus (EBV), and coexpression of PD-1 and PD-L1 was a favourable prognostic marker that showed a dose effect on the mortality risk of GC patients. 17 In another study, multivariate analysis indicated that PD-1/PD-L1 expression related to a poor prognosis in patients with GC was upregulated on T cells, which was an independent prognostic indicator in patients with GC. 44 Min-joo Ahn observed in a clinical case report that anti-PD-1 therapy targeting the PD-1 gene as an immune checkpoint marker combined with stereotactic radiosurgery (SRS) was successfully performed on a GC patient with brain metastasis. 45 In gastric carcinoma, Oki, E et al revealed that MKN-45 cells expressing PD-1 were associated with poor survival and that PD-1 overexpression was significantly correlated with tumour invasion. 46 They also found that knockdown of HER2 can directly decrease PD-1 protein expression in GC cells. LMP2A is certainly expressed in the majority of Epstein-Barr virus-associated gastric cancer (EBVaGC) patients 47, 48 ; however, PD-1 was found to be upregu- 
| IN LIVER C AN CER

PD-1 is involved in hepatitis B virus (HBV) infection
| IN OTHER C AN CER S
In oesophageal cancer, a previous study showed that MutL homologue 1 (MLH1) expression was closely correlated with prognosis and may be a predictive factor for the response to preoperative therapy, and low MLH1 expression may promote tumour PD-L1 expression in oesophageal cancer. 69 Furthermore, another study found that PD-L1 plays a critical role in promoting the Epithelial-Mesenchymal Transition (EMT) EMT phenotype of human oesophageal cancer Eca-109 cells. 70 As an anti-PD-1 antibody, SHR-1210 has a manageable safety profile and promising antitumour activity in advanced oesophageal squamous cell carcinoma (ESCC) patients. 71 However, extratumoral PD-1 blockade did not perpetuate obesity-associated inflammation in oesophageal adenocarcinoma, and further studies are required to identify the negative impact of concomitant therapies on PD-1 expression in ESCC. 72 The results of a meta-analysis indicated that the PD-L1 positive rate was associated with pancreatic ductal adenocarcinoma (PDAC)
T stages, and PDAC patients with high expression levels of PD-L1
had significantly reduced overall survival. 73 The JAK-STAT signal- 
| PD -1/PD -L1 INHIB ITOR S IN C AN CER
| CON CLUS I ON S AND PER S PEC TIVE S
As an immune checkpoint molecule, PD-1 plays a vital role in suppressing the antitumour T cell-mediated immune response in the tumour microenvironment. PD-1 expression has been correlated with a poor prognosis in patients with gastrointestinal tract cancers.
Notably, cancer immunotherapy targeting immune checkpoints is a promising novel treatment strategy. 
